Interferon beta-1a is a form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis. Human interferon beta (166 residues), glycosylated, MW=22.5kD.
- Mechanism
- Curator reviewed
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
- Primary indication
- For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatumCurator reviewed · 1 structured indication
- Formula / weight
- C908H1408N246O252S7 · 20027.0 Da
- First approval
- Canada, 1998 · United States, 1996 · European Union, 2016
- Also known as
- IFN β-1a · IFN-β1a · IFNβ 1a · IFNβ-1a · Interferon beta 1-a
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Interferon beta-1a, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account